Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479580 | 0.92 | GSK3A (0.39) | GSK3AGSK3BTGFBR1ALDH1A1ROCK2 | |
| SCHEMBL646932 | 0.91 | CYP1A2 (0.41) | GSK3AGSK3BTGFBR1ALDH1A1PDE5A | |
| SCHEMBL644186 | 0.90 | KCNH2 (0.35) | ALDH1A1PDE5AKCNH2MCHR1CYP3A4 | |
| SCHEMBL646147 | 0.90 | KCNH2 (0.37) | GSK3AGSK3BALDH1A1KCNH2MCHR1 | |
| SCHEMBL643850 | 0.90 | KIF11 (0.35) | KCNH2MAOBPTGER3 | |
| SCHEMBL645975 | 0.89 | MAOB (0.33) | KCNH2MAOBPTGER3 | |
| SCHEMBL643824 | 0.88 | CYP1A2 (0.38) | PDE5AKCNH2MCHR1CYP3A4MAPT | |
| SCHEMBL643998 | 0.83 | KIF11 (0.39) | KCNH2MAOBPTGER3 | |
| SCHEMBL645288 | 0.82 | KCNH2 (0.44) | ALDH1A1PDE5AKCNH2MCHR1MAPT | |
| SCHEMBL645836 | 0.82 | MAOB (0.38) | GSK3BALDH1A1MAPTSMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | claimed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-1511734-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | GSK3A 2442/4885GSK3B 2784/4885TGFBR1 4534/4885 |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | TOP2A, TOP2B, TOP1 | GSK3A 610/4885GSK3B 635/4885TGFBR1 3882/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | GSK3A 1458/4885GSK3B 1435/4885TGFBR1 4704/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | GSK3A 1458/4885GSK3B 1435/4885TGFBR1 4704/4885 |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | GSK3A 1458/4885GSK3B 1435/4885TGFBR1 4704/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | GSK3A 1458/4885GSK3B 1435/4885TGFBR1 4704/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | GSK3A 1458/4885GSK3B 1435/4885TGFBR1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.